VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients

Therapeutic Drug Monitoring

Volumn 30, Issue 4, 2008, Pages 497-503

  Sakaeda, Toshiyuki ^a   Yamamori, Motohiro ^b   Kuwahara, Akiko ^b   Hiroe, Satoko ^b   Nakamura, Tsutomu ^b,c   Okumura, Katsuhiko ^b,c   Okuno, Tatsuya ^b,c   Miki, Ikuya ^c   Chayahara, Naoko ^b,c   Okamura, Noboru ^c   Tamura, Takao ^c  

^a KYOTO UNIVERSITY   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Area under concentration time curve; Esophageal squamous cell carcinoma; Genetic polymorphisms; Therapeutic drug monitoring; Vascular endothelial growth factor

Indexed keywords

CISPLATIN; FLUOROURACIL; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; VASCULOTROPIN A;

ADULT; ADVERSE DRUG REACTION; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CHEILITIS; CLINICAL ARTICLE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; JAPANESE; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; STOMATITIS; TREATMENT RESPONSE; ESOPHAGUS TUMOR; GENETICS; GENOTYPE; JAPAN; MIDDLE AGED; PREDICTION AND FORECASTING; RADIOTHERAPY; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58149111246     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318180e3d2     Document Type: Article

References (38)

1. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623-1627.
2. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167-1174.
3. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915-2921.
4. Kaneko K, Ito H, Konishi K, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003;88:18-24.
5. Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425-433.
6. Tahara M, Ohtsu A, Hironaka S, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol. 2005;35:316-323.
7. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:2697-2702.
8. van den Bongard HJ, Mathô t RA, Beijnen JH, et al. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet. 2000;39:345-367.
9. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet. 2006;45:567-592.
10. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
11. Criscuolo GR, Merrill MJ, Oldfield EH. Further characterization of malignant glioma-derived vascular permeability factor. J Neurosurg. 1988;69:254-262.
12. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-858.
13. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84:1470-1478.
14. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
15. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309-1312.
16. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signaling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-371.
17. Han W, Yu Y, Liu XY. Local signals in stem cell-based bone marrow regeneration. Cell Res. 2006;16:189-195.
18. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2001;2: 667-673.
19. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/ VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109:227-241.
20. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett. 2006;580:2879-2887.
21. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002; 417:954-958.
22. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8:831-840.
23. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med. 2002;8:841-849.
24. Yamamori M, Sakaeda T, Nakamura T, et al. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun. 2004;325:144-150.
25. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002;13:260-264.
26. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51:1635-1639.
27. Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37: 443-448.
28. Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003;106:468-471.
29. Koukourakis MI, Papazoglou D, Giatromanolaki A, et al. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004;46:293-298.
30. Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group (The Clinical Trial Review Committee of the Japan Clinical Oncology Group). Jpn J Clin Oncol. 1993;23:250-257.
31. Miki I, Tamura T, Nakamura T, et al. Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther Drug Monit. 2005; 27:369-374.
32. Okuno T, Tamura T, Yamamori M, et al. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for Stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol. 2007; 30:252-257.
33. Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203-2206.
34. Loh GW, Ting LS, Ensom MH. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin Pharmacokinet. 2007;46:471-494.
35. Arbiser JL, Johnson D, Cohen C, et al. High-level expression of vascular endothelial growth factor and its receptors in an aphthous ulcer. J Cutan Med Surg. 2003;7:225-228.
36. Brozovic S, Vucicevic-Boras V, Mravak-Stipetic M, et al. Salivary levels of vascular endothelial growth factor (VEGF) in recurrent aphthous ulceration. J Oral Pathol Med. 2002;31:106-108.
37. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003;34:383-394.
38. Prior SJ, Hagberg JM, Paton CM, et al. DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am J Physiol Heart Circ Physiol. 2006; 290:1848-1855.